Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mesynthes Ltd.

www.mesynthes.com

Latest From Mesynthes Ltd.

Biologics: The Growth Engine in Advanced Wound Care

With estimated revenues in excess of $5 billion per year worldwide, the advanced wound care market has garnered the attention of both major companies and investors for its tremendous potential. Growth in this market is being driven by the development of new bioactive products that can successfully heal chronic wounds such as diabetic foot ulcers, which are among the most challenging and costly to treat.
Medical Device

Mesynthes Ltd.

Mesynthes Ltd.'s soft tissue regeneration and reconstruction platform, based on a proprietary extracellular matrix derived from the sheep forestomach, provides a biological template for tissue repair. Animal studies have demonstrated that the architecture of the matrix--including the vascular channels and the structural, fibrillar, and adhesive proteins, such as collagen and elastin--supports the ingress and growth of keratinocytes, fibroblasts, and mesenchymal and inflammatory cells. The extracellular matrix also releases important biological macromolecules that trigger tissue regeneration.
Medical Device

Start-Up Previews (10/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "It’s Apples vs. Oranges in the PI3 Kinase Race," features profiles of Arno Therapeutics, Intellikine and Paloma Pharmaceuticals. Plus these Start-Ups Across Health Care: Mesynthes, Miracor Medical Systems, Silicos, Vantia and Vexim.

Start-Up News

Noteworthy news from medtech start-ups. This month we profile Anteis, which is developing next generation hyaluronic acid products for the aesthetics and ophthalmology markets, and Mesyenthes, which is developing an extracellular matrix implant for soft tissue applications.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • New Zealand
  • Parent & Subsidiaries
  • Mesynthes Ltd.
  • Senior Management
  • Brian Ward, CEO
  • Contact Info
  • Mesynthes Ltd.
    Phone: (64) 4 931 3275
    69 Gracefield Rd.
    Seaview
    P.O. Box 31311 Lower Hutt, 5040
    New Zealand
Advertisement
Advertisement
UsernamePublicRestriction

Register